07:01:51 EDT Thu 20 Jun 2019
Enter Symbol
or Name

Login ID:

News for U:ICOTF from 2018-06-21 to 2019-06-20 - 16 items News ReleasesIn The NewsOther
2019-05-30 16:42ICOTFNews ReleaseiCo Therapeutics Announces First Quarter 2019 Financial Results
2019-04-30 18:39ICOTFNews ReleaseiCo Therapeutics Announces 2018 Year End Financial Results
2019-03-05 07:26ICOTFNews ReleaseiCo Therapeutics Inc. Announces the Issuance of 3,600,000 Units Pursuant to its Non-Brokered Private Placement
2019-02-25 08:01ICOTFNews ReleaseiCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement
2019-02-19 06:01ICOTFNews ReleaseiCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN
2019-02-19 05:46ICOTFNews ReleaseiCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008)
2019-02-11 19:20ICOTFNews ReleaseiCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement
2019-01-31 20:07ICOTFNews ReleaseiCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000
2018-11-29 17:00ICOTFNews ReleaseiCo Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Update
2018-11-15 08:01ICOTFNews ReleaseiCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study
2018-10-23 08:00ICOTFNews ReleaseiCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board
2018-10-02 08:00ICOTFNews ReleaseiCo Therapeutics Provides Corporate Update
2018-09-06 08:00ICOTFNews ReleaseiCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference
2018-08-29 18:32ICOTFNews ReleaseiCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update
2018-07-16 08:01ICOTFNews ReleaseiCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B
2018-06-27 08:00ICOTFNews ReleaseiCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study